Year 2017 / Volume 109 / Number 12
Editorial
Disruptive therapeutic innovation and the opportunity to eliminate a chronic disease – The issue of chronic hepatitis C in Spain

807-808

DOI: 10.17235/reed.2017.5384/2017

Conrado M. Fernández Rodríguez,

Abstract
Public funding decisions must be guided by criteria of scientific evidence, cost-effectiveness and economic evaluation. As an increase in health-effectiveness provided by therapeutic innovations can also substantially raise the cost, the cost-effectiveness analysis estimating this increase in the cost per unit of health gained compared to the previous technologies should be part of the economic evaluation. The measure of effectiveness most frequently used in health economic evaluations is the Quality Adjusted Life Year (QALY). Data from a Markov analysis presented by Turnes et al. in the last issue of this journal comparing two scenarios, pre-DAA and post-DAA in Spain is discussed in this document.
Share Button
New comment
Comments
No comments for this article
References
1. Christensen CM, Rosenbloom RS. Explaining the attacker's advantage: Technological paradigms, organizational dynamics, and the value network. Research Policy 1995;24:233-25
2. Plan estratégico para el abordaje de la hepatitis C en el sistema Nacional de salud. Ministerio de sanidad, servicios sociales e igualdad, 21 de Mayo de 2015.
3. Fernández Carrillo C, Lens S, Llop E, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. Hepatology. 2017; 65:1810-1822.
4. Perelló C, Carrión JA, Ruiz-Antorán B, et al; Spanish Collaborative Group for the Study of the Use of Hepatitis C Direct-Acting Drugs.. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. J Viral Hepat. 2017;24:226-237.
5. Muñoz-Gómez R, Rincón D, Ahumada A, et al. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience. J Viral Hepat. 2017;24:464-471.
6. Alonso S, Riveiro-Barciela M, Fernandez I, et al. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. J Viral Hepat. 2017; 24:304-311.
7. Vallejo-Torres L, García-Lorenzo B, García-Pérez L, et al. Valor Monetario de un Año de Vida Ajustado por Calidad: Revisión y Valoración Crítica de la Literatura. Ministerio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluación del Servicio Canario de la Salud; 2014. Informes de Evaluación de Tecnologías Sanitarias.
8. Vallejo-Torres L, García-Lorenzo B, Castilla I, et al.; en representación de RedETS y REDISSEC. Estimación de un umbral coste-efectividad en España. ¿Cuánto nos cuesta generar salud? Revista Española de Economía de la Salud 2016; 11: 3: 405-408
9. Turnes J, Domínguez Hernández R, Casado MA. Value and innovation of direct-acting antivirals: Long-term health outcomes of the strategic plan for management of hepatitis C in Spain. Rev Esp Enf Dig 2017; 109:xxx-xxx
10. http://www.senado.es/legis12/publicaciones/pdf/senado/ds/DS_C_12_44.PDF. Acceso el 16 de Noviembre de 2017.
Related articles
Citation tools
Fernández Rodríguez C. Disruptive therapeutic innovation and the opportunity to eliminate a chronic disease – The issue of chronic hepatitis C in Spain. 5384/2017


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 239 visits.
This article has been downloaded 160 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 20/11/2017

Accepted: 21/11/2017

Online First: 23/11/2017

Published: 04/12/2017

Article Online First time: 3 days

Article editing time: 14 days


Share
This article has been rated by 8 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology